Literature DB >> 32426047

Novel antibody-drug conjugates for triple negative breast cancer.

Aiko Nagayama1, Neelima Vidula2, Leif Ellisen2, Aditya Bardia3.   

Abstract

Triple negative breast cancer (TNBC) is a heterogenous subtype of breast cancer often associated with an aggressive phenotype and poor prognosis. Antibody-drug conjugate (ADC), comprising of a monoclonal antibody linked to a cytotoxic payload by a linker, is gaining increasing traction as an anti-cancer therapeutic. Emerging ADC drugs such as sacituzumab govitecan (IMMU-132) and trastuzumab deruxtecan (DS-8201a) are in late stages of clinical development for patients with metastatic breast cancer, including TNBC. In this article, we review and discuss the development and clinical application of ADCs in patients with advanced TNBC.
© The Author(s), 2020.

Entities:  

Keywords:  antibody–drug conjugates; breast cancer; triple negative breast cancer

Year:  2020        PMID： 32426047      PMCID： PMC7222243          DOI： 10.1177/1758835920915980

Source DB:  PubMed          Journal:  Ther Adv Med Oncol        ISSN： 1758-8340            Impact factor:   8.168


  45 in total

Review 1.  Strategies and challenges for the next generation of antibody-drug conjugates.

Authors:  Alain Beck; Liliane Goetsch; Charles Dumontet; Nathalie Corvaïa
Journal:  Nat Rev Drug Discov       Date:  2017-03-17       Impact factor: 84.694

2.  Synthetic Lethality Exploitation by an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, IMMU-132, Plus PARP Inhibitors in BRCA1/2-wild-type Triple-Negative Breast Cancer.

Authors:  Thomas M Cardillo; Robert M Sharkey; Diane L Rossi; Roberto Arrojo; Ali A Mostafa; David M Goldenberg
Journal:  Clin Cancer Res       Date:  2017-01-09       Impact factor: 12.531

3.  Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.

Authors:  P F Bross; J Beitz; G Chen; X H Chen; E Duffy; L Kieffer; S Roy; R Sridhara; A Rahman; G Williams; R Pazdur
Journal:  Clin Cancer Res       Date:  2001-06       Impact factor: 12.531

4.  A Novel HER3-Targeting Antibody-Drug Conjugate, U3-1402, Exhibits Potent Therapeutic Efficacy through the Delivery of Cytotoxic Payload by Efficient Internalization.

Authors:  Yuuri Hashimoto; Kumiko Koyama; Yasuki Kamai; Kenji Hirotani; Yusuke Ogitani; Akiko Zembutsu; Manabu Abe; Yuki Kaneda; Naoyuki Maeda; Yoshinobu Shiose; Takuma Iguchi; Tomomichi Ishizaka; Tsuyoshi Karibe; Ichiro Hayakawa; Koji Morita; Takashi Nakada; Taisei Nomura; Kenichi Wakita; Takashi Kagari; Yuki Abe; Masato Murakami; Suguru Ueno; Toshinori Agatsuma
Journal:  Clin Cancer Res       Date:  2019-08-30       Impact factor: 12.531

5.  Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study.

Authors:  Barbara Pro; Ranjana Advani; Pauline Brice; Nancy L Bartlett; Joseph D Rosenblatt; Tim Illidge; Jeffrey Matous; Radhakrishnan Ramchandren; Michelle Fanale; Joseph M Connors; Yin Yang; Eric L Sievers; Dana A Kennedy; Andrei Shustov
Journal:  J Clin Oncol       Date:  2012-05-21       Impact factor: 44.544

Review 6.  Trop2: from development to disease.

Authors:  Annie R A McDougall; Mary Tolcos; Stuart B Hooper; Timothy J Cole; Megan J Wallace
Journal:  Dev Dyn       Date:  2015-02       Impact factor: 3.780

7.  Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate.

Authors:  Nicole M Okeley; Jamie B Miyamoto; Xinqun Zhang; Russell J Sanderson; Dennis R Benjamin; Eric L Sievers; Peter D Senter; Stephen C Alley
Journal:  Clin Cancer Res       Date:  2010-01-19       Impact factor: 12.531

8.  DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1.

Authors:  Yusuke Ogitani; Tetsuo Aida; Katsunobu Hagihara; Junko Yamaguchi; Chiaki Ishii; Naoya Harada; Masako Soma; Hiromi Okamoto; Masataka Oitate; Shingo Arakawa; Takehiro Hirai; Ryo Atsumi; Takashi Nakada; Ichiro Hayakawa; Yuki Abe; Toshinori Agatsuma
Journal:  Clin Cancer Res       Date:  2016-03-29       Impact factor: 12.531

9.  Ror2 Signaling and Its Relevance in Breast Cancer Progression.

Authors:  Michaela Bayerlová; Kerstin Menck; Florian Klemm; Alexander Wolff; Tobias Pukrop; Claudia Binder; Tim Beißbarth; Annalen Bleckmann
Journal:  Front Oncol       Date:  2017-06-26       Impact factor: 6.244

Review 10.  Understanding the biology of HER3 receptor as a therapeutic target in human cancer.

Authors:  Hui Lyu; Amy Han; Erik Polsdofer; Shuang Liu; Bolin Liu
Journal:  Acta Pharm Sin B       Date:  2018-06-02       Impact factor: 11.413
View more
  23 in total

Review 1.  Nano to rescue: repository of nanocarriers for targeted drug delivery to curb breast cancer.

Authors:  Poonam Banthia; Lokesh Gambhir; Asha Sharma; Dhiraj Daga; Neha Kapoor; Rishabh Chaudhary; Gaurav Sharma
Journal:  3 Biotech       Date:  2022-02-13       Impact factor: 2.406

2.  Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer.

Authors:  James T Coates; Sheng Sun; Ignaty Leshchiner; Nayana Thimmiah; Elizabeth E Martin; Daniel McLoughlin; Brian P Danysh; Kara Slowik; Raquel A Jacobs; Kahn Rhrissorrakrai; Filippo Utro; Chaya Levovitz; Elyssa Denault; Charlotte S Walmsley; Avinash Kambadakone; James R Stone; Steven J Isakoff; Laxmi Parida; Dejan Juric; Gad Getz; Aditya Bardia; Leif W Ellisen
Journal:  Cancer Discov       Date:  2021-08-17       Impact factor: 39.397

Review 3.  Nanobiotherapeutic strategies to target immune microenvironment of triple-negative breast cancer.

Authors:  Qing Chang; Liang Chang; Mo Li; Liwen Fan; Shunchao Bao; Xinyu Wang; Linlin Liu
Journal:  Am J Cancer Res       Date:  2022-09-15       Impact factor: 5.942

4.  [89Zr]ZrDFO-CR011 PET Correlates with Response to Glycoprotein Nonmetastatic Melanoma B-targeted Therapy in Triple-negative Breast Cancer.

Authors:  Supum Lee; Alessandra Cavaliere; Jean-Dominique Gallezot; Tibor Keler; Sharon K Michelhaugh; Erika Belitzky; Michael Liu; Tim Mulnix; Stephen E Maher; Alfred L M Bothwell; Fangyong Li; Manali Phadke; Sandeep Mittal; Bernadette Marquez-Nostra
Journal:  Mol Cancer Ther       Date:  2022-03-01       Impact factor: 6.009

5.  Antibody-drug conjugate MORAb-202 exhibits long-lasting antitumor efficacy in TNBC PDx models.

Authors:  Keiji Furuuchi; Katherine Rybinski; James Fulmer; Tomoyuki Moriyama; Brian Drozdowski; Allis Soto; Shawn Fernando; Kerrianne Wilson; Andrew Milinichik; Mary Lou Dula; Keigo Tanaka; Xin Cheng; Earl Albone; Toshimitsu Uenaka
Journal:  Cancer Sci       Date:  2021-05-01       Impact factor: 6.716

6.  LRRC15 antibody-drug conjugates show promise as osteosarcoma therapeutics in preclinical studies.

Authors:  Katherine K Slemmons; Sanjit Mukherjee; Paul Meltzer; James W Purcell; Lee J Helman
Journal:  Pediatr Blood Cancer       Date:  2020-10-16       Impact factor: 3.838

Review 7.  Therapeutic Advances in Oncology.

Authors:  Jinsha Liu; Priyanka Pandya; Sepideh Afshar
Journal:  Int J Mol Sci       Date:  2021-02-18       Impact factor: 5.923

Review 8.  Drug Repurposing for Triple-Negative Breast Cancer.

Authors:  Marta Ávalos-Moreno; Araceli López-Tejada; Jose L Blaya-Cánovas; Francisca E Cara-Lupiañez; Adrián González-González; Jose A Lorente; Pedro Sánchez-Rovira; Sergio Granados-Principal
Journal:  J Pers Med       Date:  2020-10-29

Review 9.  Sacituzumab govitecan and trastuzumab deruxtecan: two new antibody-drug conjugates in the breast cancer treatment landscape.

Authors:  E Adams; H Wildiers; P Neven; K Punie
Journal:  ESMO Open       Date:  2021-07-02

Review 10.  Antibody-Drug Conjugates Used in Breast Cancers.

Authors:  Aram J Abbas; Marah F Ibrahim; Maher S Saifo
Journal:  J Oncol       Date:  2021-06-24       Impact factor: 4.375
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.